

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INTERNATIONAL GENIUS COMPANY

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 33)

- (1) APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF ECONOMIST;**
- (2) RESIGNATION OF DIRECTORS;**
- (3) CHANGE OF AUTHORISED REPRESENTATIVE; AND**
- (4) CHANGE OF COMPOSITION OF BOARD COMMITTEE**

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF ECONOMIST

The board (the “**Board**”) of directors (“**Directors**”) of International Genius Company (the “**Company**”) together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. He Xiaobin (“**Dr. He**”) has been appointed as an executive director and chief economist with effect from 25 April 2024. The biography of Dr. He is set out as follows:

Dr. He Xiaobin, male, aged 61, holds a doctoral degree in economics and is a senior economist. He has more than 30 years of working experience in futures investment and corporate compliance, and has extensive financial knowledge and management experience.

Dr. He served as the director of the Futures Supervision Division of the Shanghai Securities Regulatory Bureau of the China Securities Regulatory Commission (中國證監會上海證監局期貨監管處處長), and the deputy director of the Resource and Energy Division of the Shanghai Municipal Planning Committee (上海市計劃委員會物資能源處副處長). Dr. He also served as the chairman of Guotai Junan Futures (國泰君安期貨), the secretary to the board of directors of Guotai Junan Securities (國泰君安證券), the president of Guotai Junan Asset Management (國泰君安資產管理公司), the chief economist of Huaxin Securities (華鑫證券) and the chairman of Huaxin Futures (華鑫期貨), a director of the China Chief Economist Forum (中國首席經濟學家論壇), a member of the Chief Economist Committee of the Securities Association of China (中國證券業協會), and a director of Shenergy Co., Ltd. (a company listed on the Shanghai Stock Exchange with stock code: 600642). Dr. He is entitled to special allowance from the State Council of the People’s Republic of China, was selected as one of the top ten financial industry leaders in Shanghai, and was an adjunct professor at Shanghai Jiao Tong University and Tongji University. Dr. He was an independent non-executive

director of Target Insurance (Holdings) Limited (a company delisted from the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with previous stock code: 6161), from Mar 2023 to Jan 2024.

Dr. He has entered into a letter of appointment with the Company for a term of three years and his appointment can be terminated by either party giving three months’ prior written notice. In accordance with the articles of association of the Company and the Listing Rules, Dr. He will hold office until the next annual general meeting of the Company at which time he will be eligible for re-election and his appointment would be subject to retirement by rotation. Dr. He will be entitled to a remuneration of HK\$600,000 per annum for his role as an executive director and chief economist, which was determined with reference to his background, qualifications, experience, duties and responsibilities to the Company and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Dr. He does not (i) hold any other positions in the Company or its subsidiaries; (ii) hold any directorship in other public companies the securities of which are listed in Hong Kong or overseas in the last three years; (iii) have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) have, and is not deemed to have, any interests or short positions (both within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) in the shares, underlying shares or debentures of the Company or any of its associated corporation (as defined under Part XV of the Securities and Futures Ordinance).

Save as disclosed above, there is no other information in relation to the appointment of Dr. He which is required to be disclosed nor is/was he involved in any of the matters required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules; and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend a welcome to Dr. He for joining the Board.

RESIGNATION OF DIRECTORS

The Board announces that:

- i. Dr. Lin Feng (“**Dr. Lin**”) has tendered his resignation as an executive director of the Company with effect from 25 April 2024. Upon the Resignation of Dr. Lin, he would also cease to act as an authorised representative (the “**Authorised Representative**”) of the Company required under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on the Stock Exchange, the chairman of risk management committee and a member of each of the executive committee and the nomination committee of the Company; and
- ii. Ms. Sun Qiuzhen (“**Ms. Sun**”) has tendered her resignation as a non-executive director of the Company with effect from 25 April 2024.

Both Dr. Lin and Ms. Sun have confirmed that his/her resignation was due to his/her decision to devote more time to his other business commitments.

Both of Dr. Lin and Ms. Sun confirmed that he/she has no disagreement with the Board during his/her tenure of office and there is no matter which has to be brought to the attention of the shareholders of the Company and the Stock Exchange in relation to his/her resignation.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Lin and Ms. Sun for their valuable contributions to the Company during their tenure of office.

CHANGE OF AUTHORISED REPRESENTATIVE

Following the resignation of Dr. Lin, Dr. He has been appointed as the Authorised Representative with effect from 25 April 2024.

CHANGE OF COMPOSITION OF BOARD COMMITTEE

The Board also announces that, with effect from 25 April 2024, Dr. He has been appointed as the chairman of the risk management committee and a member of each of the executive committee and nomination committee of the Company.

By Order of the Board
International Genius Company
Mr. Cheung Ka Fai
Company Secretary

Hong Kong, 25 April 2024

As at the date of this announcement, (i) the executive Director of the Company is Dr. He Xiaobin; (ii) the non-executive Director of the Company is Mr. Dai Chengyan and (iii) the independent non-executive Directors of the Company are Mr. Lo Hang Fong, Mr. Wang Jun Sheng and Mr. Yip Tze Wai Albert.